Skip to main content

PCSK9 inhibitors


09-18-2017 | PCSK9 inhibitors | EASD 2017 | News

FOURIER: Evolocumab cardiovascular benefits extend to diabetes patients

A prespecified analysis of the FOURIER trial shows that the PCSK9 inhibitor evolocumab is as beneficial in patients with diabetes as in those without.

09-14-2017 | PCSK9 inhibitors | EASD 2017 | News

Alirocumab dyslipidemia benefits extended to type 1 patients

The effect of the PCSK9 inhibitor alirocumab on dyslipidemia in patients with type 1 diabetes is consistent with that seen in the type 2 population, the ODYSSEY team has revealed.

Read more

Related topics



Journal articles and book chapters

10-26-2018 | PCSK9 inhibitors | Review | Article

Inhibiting PCSK9: Biology beyond LDL control

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

06-25-2018 | Cardiovascular disorders | Review | Article

Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment

Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5

09-16-2016 | Dyslipidemia | Review | Article

PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD

​​​​​​​Nat Rev Endocrinol 2017; 13: 36–49. doi: 10.1038/nrendo.2016.135